In Brief: Taro
This article was originally published in The Tan Sheet
Executive Summary
Taro: First Phase III trials of the generic drug company's prescription one-day treatment for vaginal yeast infections are complete. Taro plans to file an NDA in 1998 and is seeking a multinational partner for co-marketing of store brand and branded product. Taro is also talking to companies interested in its "NonSpil" technology for drug delivery; the pourable substance will remain in a spoon that has been turned upside down. The initial patent application was filed in April 1993...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning